X-linked Alport syndrome

Summary

X-linked Alport syndrome (MONDO:0010520) is a disease caused by COL4A5 (GenCC Definitive), with 6 cohort genes and 3 clinical trials. The dominant Reactome pathway is Fibronectin matrix formation (3 cohort genes). Top therapeutic interventions include benazepril, hydroxychloroquine, and elx-02.

At a glance

• Prevalence: 1-9 / 100 000 (Sweden) [Orphanet-validated]
• Causal gene: COL4A5 (GenCC Definitive)
• Cohort genes: 6
• ClinVar variants: 1,310
• Clinical trials: 3

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Prevalence at birth	1-9 / 100 000	1.25	Sweden	Validated
Point prevalence	1-9 / 100 000		Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	X-linked Alport syndrome
Mondo ID	MONDO:0010520
OMIM	301050
Orphanet	88917
DOID	DOID:0110034
SNOMED CT	717768004
UMLS	C4746986
MedGen	1648433
GARD	0016774
MedDRA	10001843
Is cancer (heuristic)	no

Also known as: Alport syndrome 1, X-linked, X-linked dominant · Alport syndrome, X-linked · ATS · congenital hereditary hematuria · hemorrhagic familial nephritis · hemorrhagic hereditary nephritis · nephropathy and deafness, X-linked · X-linked Alport syndrome

Data availability: 1,310 ClinVar variants · 4 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › X-linked disease › X-linked Alport syndrome

Related subtypes (49): X-linked Opitz G/BBB syndrome, X-linked immunoneurologic disorder, X-linked adrenal hypoplasia congenita, X-linked lissencephaly with abnormal genitalia, X-linked severe congenital neutropenia, X-linked distal spinal muscular atrophy type 3, epilepsy, X-linked 1, with variable learning disabilities and behavior disorders, Aland island eye disease, X-linked erythropoietic protoporphyria, X-linked central congenital hypothyroidism with late-onset testicular enlargement, X-linked colobomatous microphthalmia-microcephaly-intellectual disability-short stature syndrome, X-linked acrogigantism due to Xq26 microduplication, Wiskott-Aldrich syndrome, X-linked mandibulofacial dysostosis, X-linked chondrodysplasia punctata, choroideremia, cone dystrophy, X-linked, with tapetal-like sheen, diabetes insipidus, nephrogenic, X-linked, Dyggve-Melchior-Clausen syndrome, X-linked, dyskeratosis congenita, X-linked, X-linked hypohidrotic ectodermal dysplasia, X-linked Ehlers-Danlos syndrome, epidermodysplasia verruciformis, X-linked, exudative vitreoretinopathy 2, X-linked, Aarskog-Scott syndrome, X-linked, hemophilia A, X-linked hydrocephalus with stenosis of the aqueduct of Sylvius, hyper-IgM syndrome type 1, X-linked lymphoproliferative syndrome, macular dystrophy, X-linked, X-linked Emery-Dreifuss muscular dystrophy, X-linked myotubular myopathy, X-linked lethal multiple pterygium syndrome, X-linked retinoschisis, spondyloepiphyseal dysplasia tarda, X-linked, X-linked cerebellar ataxia, adrenoleukodystrophy, Charcot-Marie-Tooth disease type X, X-linked dominant disease, X-linked recessive disease, X-linked hypophosphatemic rickets, X-linked sideroblastic anemia 1, X-linked deafness, X-linked cone-rod dystrophy, X-linked congenital stationary night blindness, X-linked congenital hemolytic anemia, X-linked complex neurodevelopmental disorder, X-linked intellectual disability, leukemia, acute, X-linked

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

600 retrieved; paginated sample, class counts are floors:

178 likely pathogenic, 138 pathogenic, 86 pathogenic/likely pathogenic, 75 uncertain significance, 55 conflicting classifications of pathogenicity, 28 likely benign, 21 benign, 19 benign/likely benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
10460	Multiple alleles		Pathogenic	no assertion criteria provided
10464	NM_033380.2(COL4A5):c.[866G>T;4282C>T]		Pathogenic	no assertion criteria provided
10453	NG_011977.2:g.(239831_242576)_(252772_257824)del	COL4A5	Pathogenic	no assertion criteria provided
10455	COL4A5, 10-15-KB INS, 40-KB DEL	COL4A5	Pathogenic	no assertion criteria provided
10456	NG_011977.2:g.(246966_251107)_?del	COL4A5	Pathogenic	no assertion criteria provided
10457	NG_011977.2:g.?_(146097_162513)del	COL4A5	Pathogenic	no assertion criteria provided
10458	NM_033380.3(COL4A5):c.3428G>A (p.Gly1143Asp)	COL4A5	Pathogenic	criteria provided, single submitter
10462	NM_033380.3(COL4A5):c.1561G>T (p.Gly521Cys)	COL4A5	Pathogenic	no assertion criteria provided
10463	NM_033380.3(COL4A5):c.974G>A (p.Gly325Glu)	COL4A5	Pathogenic	no assertion criteria provided
10465	NM_033380.3(COL4A5):c.161G>A (p.Gly54Asp)	COL4A5	Pathogenic	no assertion criteria provided
10466	NM_033380.3(COL4A5):c.4964T>G (p.Leu1655Arg)	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
10467	NM_033380.3(COL4A5):c.5048G>A (p.Arg1683Gln)	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1066338	NM_033380.3(COL4A5):c.2998G>A (p.Gly1000Arg)	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1066653	NM_033380.3(COL4A5):c.2042-2A>G	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1066732	NM_033380.3(COL4A5):c.3347G>A (p.Gly1116Glu)	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1066759	NM_033380.3(COL4A5):c.3107G>A (p.Gly1036Glu)	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1067067	NM_033380.3(COL4A5):c.1370G>A (p.Gly457Asp)	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1068943	NM_033380.3(COL4A5):c.4528+2T>C	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1072946	NM_033380.3(COL4A5):c.1862G>A (p.Gly621Asp)	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1073265	NM_033380.3(COL4A5):c.4706+2T>C	COL4A5	Pathogenic	criteria provided, multiple submitters, no conflicts
1073893	NM_033380.3(COL4A5):c.4706+1G>T	COL4A5	Pathogenic	criteria provided, multiple submitters, no conflicts
1075985	NM_033380.3(COL4A5):c.3584dup (p.Gly1196fs)	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1076557	NM_033380.3(COL4A5):c.874G>A (p.Gly292Arg)	COL4A5	Pathogenic	criteria provided, multiple submitters, no conflicts
1076952	NM_033380.3(COL4A5):c.1808G>A (p.Gly603Asp)	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1077037	NM_033380.3(COL4A5):c.439-1G>A	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1077042	NM_033380.3(COL4A5):c.4978_4979insAAAA (p.Val1660fs)	COL4A5	Pathogenic	criteria provided, single submitter
1077043	NM_033380.3(COL4A5):c.1871G>T (p.Gly624Val)	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1077046	NM_033380.3(COL4A5):c.2146G>A (p.Gly716Ser)	COL4A5	Pathogenic	criteria provided, single submitter
1077047	NM_033380.3(COL4A5):c.1033-2A>G	COL4A5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1077050	NM_033380.3(COL4A5):c.1480G>T (p.Gly494Cys)	COL4A5	Pathogenic	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 6 · Orphanet: 9 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
COL4A5	Definitive	X-linked	Alport syndrome	6

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
COL4A5	Orphanet:1018	X-linked Alport syndrome-diffuse leiomyomatosis
COL4A5	Orphanet:653722	Digenic Alport syndrome
COL4A5	Orphanet:88917	X-linked Alport syndrome
COL4A4	Orphanet:653722	Digenic Alport syndrome
COL4A4	Orphanet:88918	Autosomal dominant Alport syndrome
COL4A4	Orphanet:88919	Autosomal recessive Alport syndrome
FN1	Orphanet:84090	Fibronectin glomerulopathy
FN1	Orphanet:93315	Spondylometaphyseal dysplasia, ‘corner fracture’ type
MSR1	Orphanet:1331	Familial prostate cancer

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	6

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
COL4A5	HGNC:2207	ENSG00000188153	P29400	Collagen alpha-5(IV) chain	gencc,clinvar
ATG4A	HGNC:16489	ENSG00000101844	Q8WYN0	Cysteine protease ATG4A	clinvar
COL4A4	HGNC:2206	ENSG00000081052	P53420	Collagen alpha-4(IV) chain	clinvar
ZC3H12C	HGNC:29362	ENSG00000149289	Q9C0D7	Probable ribonuclease ZC3H12C	clinvar
FN1	HGNC:3778	ENSG00000115414	P02751	Fibronectin	clinvar
MSR1	HGNC:7376	ENSG00000038945	P21757	Macrophage scavenger receptor types I and II	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
COL4A5	Collagen alpha-5(IV) chain	Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a ‘chicken-wire’ meshwork together with laminins, proteoglycans and entactin/nidogen.
ATG4A	Cysteine protease ATG4A	Cysteine protease that plays a key role in autophagy by mediating both proteolytic activation and delipidation of ATG8 family proteins.
COL4A4	Collagen alpha-4(IV) chain	Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a ‘chicken-wire’ meshwork together with laminins, proteoglycans and entactin/nidogen.
ZC3H12C	Probable ribonuclease ZC3H12C	May function as RNase and regulate the levels of target RNA species.
FN1	Fibronectin	Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin.
MSR1	Macrophage scavenger receptor types I and II	Membrane glycoproteins implicated in the pathologic deposition of cholesterol in arterial walls during atherogenesis.

Protein-family classification

Druggable: 2 · Difficult: 1 · Unknown: 3 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Protease	1	6.1×	0.377
Antibody/Immunoglobulin	1	4.9×	0.377
Transcription factor	1	1.4×	0.719
Other/Unknown	3	0.9×	0.758

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
COL4A5	Other/Unknown	no		Collagen_IV_NC, Collagen, CTDL_fold
ATG4A	Protease	yes		Peptidase_C54, Papain-like_cys_pep_sf, Peptidase_C54_cat
COL4A4	Other/Unknown	no		Collagen_IV_NC, Collagen, CTDL_fold
ZC3H12C	Transcription factor	no		Znf_CCCH, RNase_Zc3h12_NYN, Rege-1_UBA-like
FN1	Antibody/Immunoglobulin	yes		Fibronectin_type1, FN_type2_dom, FN3_dom
MSR1	Other/Unknown	no		SRCR, SR-AI/II, Collagen

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	6
unknown	0

Top tissues across cohort

Tissue	Cohort genes
lower esophagus muscularis layer	1
mucosa of stomach	1
ventricular zone	1
body of pancreas	1
gastrocnemius	1
hindlimb stylopod muscle	1
metanephros cortex	1
pigmented layer of retina	1
renal medulla	1
biceps brachii	1
epithelial cell of pancreas	1
tibialis anterior	1
decidua	1
right coronary artery	1
synovial joint	1
right lung	1
upper lobe of left lung	1
upper lobe of lung	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
COL4A5	267	ubiquitous	marker	mucosa of stomach, ventricular zone, lower esophagus muscularis layer
ATG4A	272	ubiquitous	marker	body of pancreas, gastrocnemius, hindlimb stylopod muscle
COL4A4	187	broad	marker	renal medulla, metanephros cortex, pigmented layer of retina
ZC3H12C	247	ubiquitous	yes	tibialis anterior, epithelial cell of pancreas, biceps brachii
FN1	292	ubiquitous	marker	synovial joint, right coronary artery, decidua
MSR1	206	broad	marker	right lung, upper lobe of left lung, upper lobe of lung

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
FN1	8,860
MSR1	2,259
COL4A5	1,738
COL4A4	1,243
ATG4A	1,161
ZC3H12C	570

Intra-cohort edges

A	B	Sources
COL4A4	COL4A5	string_interaction

Structural data

PDB: 5 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
FN1	P02751	65
COL4A5	P29400	2
COL4A4	P53420	2
ATG4A	Q8WYN0	1
MSR1	P21757	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
ZC3H12C	Q9C0D7	58.15

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 44. Enrichment computed across 6 evidence-associated genes (5 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Fibronectin matrix formation	3	342.6×	2e-06	COL4A5, COL4A4, FN1
Attachment of bacteria to epithelial cells	3	297.9×	2e-06	COL4A5, COL4A4, FN1
Non-integrin membrane-ECM interactions	3	92.6×	3e-05	COL4A5, COL4A4, FN1
ECM proteoglycans	3	90.2×	3e-05	COL4A5, COL4A4, FN1
Integrin cell surface interactions	3	80.6×	3e-05	COL4A5, COL4A4, FN1
Anchoring fibril formation	2	304.5×	1e-04	COL4A5, COL4A4
Crosslinking of collagen fibrils	2	228.4×	2e-04	COL4A5, COL4A4
Laminin interactions	2	152.3×	4e-04	COL4A5, COL4A4
Collagen chain trimerization	2	103.8×	6e-04	COL4A5, COL4A4
Signaling by PDGF	2	101.5×	6e-04	COL4A5, COL4A4
NCAM1 interactions	2	99.3×	6e-04	COL4A5, COL4A4
Assembly of collagen fibrils and other multimeric structures	2	80.1×	9e-04	COL4A5, COL4A4
Collagen degradation	2	70.3×	0.001	COL4A5, COL4A4
Collagen biosynthesis and modifying enzymes	2	68.2×	0.001	COL4A5, COL4A4
ALK mutants bind TKIs	1	190.3×	0.015	FN1
p130Cas linkage to MAPK signaling for integrins	1	152.3×	0.018	FN1
GRB2:SOS provides linkage to MAPK signaling for Integrins	1	142.8×	0.018	FN1
Scavenging by Class A Receptors	1	120.2×	0.020	MSR1
Binding and Uptake of Ligands by Scavenger Receptors	1	108.8×	0.021	MSR1
Syndecan interactions	1	84.6×	0.025	FN1
Integrin signaling	1	84.6×	0.025	FN1
MET activates PTK2 signaling	1	76.1×	0.026	FN1
Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	1	71.4×	0.027	FN1
Signaling by high-kinase activity BRAF mutants	1	63.4×	0.028	FN1
Molecules associated with elastic fibres	1	61.7×	0.028	FN1
MAP2K and MAPK activation	1	57.1×	0.028	FN1
Signaling by RAF1 mutants	1	55.7×	0.028	FN1
Signaling by moderate kinase activity BRAF mutants	1	50.8×	0.028	FN1
Paradoxical activation of RAF signaling by kinase inactive BRAF	1	50.8×	0.028	FN1
Signaling downstream of RAS mutants	1	50.8×	0.028	FN1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
negative regulation of monocyte activation	1	1123.5×	0.010	FN1
calcium-independent cell-matrix adhesion	1	842.6×	0.010	FN1
plasma lipoprotein particle clearance	1	842.6×	0.010	MSR1
positive regulation of substrate-dependent cell migration, cell attachment to substrate	1	842.6×	0.010	FN1
protein delipidation	1	674.1×	0.010	ATG4A
negative regulation of transforming growth factor beta production	1	674.1×	0.010	FN1
cell-substrate junction assembly	1	561.7×	0.010	FN1
biological process involved in interaction with symbiont	1	561.7×	0.010	FN1
collagen fibril organization	2	89.9×	0.010	COL4A5, COL4A4
autophagy	2	44.1×	0.010	ATG4A, FN1
positive regulation of cholesterol storage	1	481.5×	0.011	MSR1
neural crest cell migration involved in autonomic nervous system development	1	374.5×	0.012	FN1
aggrephagy	1	337.0×	0.012	ATG4A
blood coagulation, fibrin clot formation	1	337.0×	0.012	FN1
glomerular basement membrane development	1	306.4×	0.012	COL4A4
integrin activation	1	280.9×	0.012	FN1
collagen-activated tyrosine kinase receptor signaling pathway	1	259.3×	0.013	COL4A5
regulation of protein phosphorylation	1	224.7×	0.014	FN1
lipoprotein transport	1	198.3×	0.014	MSR1
enteric nervous system development	1	198.3×	0.014	FN1
piecemeal microautophagy of the nucleus	1	187.2×	0.014	ATG4A
amyloid-beta clearance	1	187.2×	0.014	MSR1
positive regulation of macrophage derived foam cell differentiation	1	168.5×	0.014	MSR1
cholesterol transport	1	146.5×	0.016	MSR1
phagocytosis, engulfment	1	134.8×	0.017	MSR1
response to muscle activity	1	116.2×	0.018	FN1
regulation of ERK1 and ERK2 cascade	1	116.2×	0.018	FN1
neuromuscular junction development	1	105.3×	0.019	COL4A5
positive regulation of axon extension	1	102.1×	0.019	FN1
endodermal cell differentiation	1	99.1×	0.019	FN1

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 5

Druggability breadth: 5 of 6 evidence-associated genes (83%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
ATG4A	TIOCONAZOLE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ATG4A	1	4
COL4A5	0	0
COL4A4	0	0
ZC3H12C	0	0
FN1	0	0
MSR1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
TIOCONAZOLE	4	ATG4A

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
ATG4A	1	Binding:1
FN1	1	Binding:1
MSR1	1	Binding:1

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
TIOCONAZOLE	4	ATG4A

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	ATG4A
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	FN1
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	4	COL4A5, COL4A4, ZC3H12C, MSR1

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
COL4A5	0	—
COL4A4	0	—
ZC3H12C	0	—
FN1	1	—
MSR1	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07523581	PHASE2	NOT_YET_RECRUITING	EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT04937907	PHASE2	COMPLETED	Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
NCT03655223	Not specified	ENROLLING_BY_INVITATION	Early Check: Expanded Screening in Newborns

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BENAZEPRIL	4	1
HYDROXYCHLOROQUINE	4	1
ELX-02	2	1